FDA Finds Gaps In Cesca's Stem Cell Trial Plan For Critical Limb Ischemia
This article was originally published in The Gray Sheet
Executive Summary
The agency noted deficiencies in Cesca Therapeutcs' investigational device exemption submission for the CLIRST III pivotal study of its SurgWerks stem cell therapy system in critical limb ischemia. But the company says the overall message for the 224-patient study is positive.
You may also be interested in...
Regenerative Medicine Firm Cesca Therapeutics Eyeing Major Device Players
The new company, forming from the merger of ThermoGenesis and TotipotentRx, aims to use its cell processing systems and cell formulations to recast the way physicians treat various cardiovascular and orthopedic problems. It is in discussions with device firms about potential partnerships.
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.